Korro Bio, Inc. (KRRO) 8-K Current Report: March 9, 2026
Filed: March 9, 2026
Health Care
Pharmaceutical PreparationsKorro Bio, Inc. (KRRO) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items4 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 2.02: Results of Operations and Financial Condition
- Item 3.02: Unregistered Sales of Equity Securities
- Item 7.01: Regulation FD Disclosure
Korro Bio, Inc. 8-K Mar 9, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • Private placement raising ~$85.0M gross proceeds via 4.5M shares at $11.11/share plus pre-funded warrants for 3.1M additional shares at $11.109 each
- • Combined with existing $85.2M cash (as of Dec 31, 2025), total runway extended into 2H 2028 — meaningful for a clinical-stage biotech burning cash on pipeline development
- • High-profile syndicate led by Venrock Healthcare, with NEA, Balyasny, Nantahala, and Driehaus among participants — institutional validation of OPERA® RNA editing platform
- • Pre-funded warrants carry 9.99% beneficial ownership blocker (adjustable to 19.99% with 61-day notice) — standard dilution management tool
- • Resale registration statement due within 30 days of closing; effectiveness deadline 60-90 days — liquidated damages triggered if deadlines missed, protecting investor liquidity
Item 2.02 · Results of Operations and Financial Condition
- • Cash, cash equivalents & marketable securities ~$85.2M as of Dec 31, 2025 (preliminary, unaudited)
- • Figure subject to change pending completion of financial closing procedures — not yet audited or reviewed by external auditors
- • Runway visibility matters for clinical-stage biotech; $85.2M balance signals near-term funding status ahead of full earnings release
Item 3.02 · Unregistered Sales of Equity Securities
- • Item 3.02 covers unregistered securities sales; KRRO's disclosure cross-references another section of this 8-K rather than detailing terms here
- • Investors should review the full 8-K for deal terms, share counts, and applicable exemptions from registration
Item 7.01 · Regulation FD Disclosure
- • Private placement closing disclosed — terms and size not specified in this section; check accompanying exhibits for deal economics
- • Preliminary unaudited year-end cash, cash equivalents, and marketable securities referenced — actual figures not disclosed in this item
- • Cash runway guidance flagged as forward-looking — subject to audit finalization risk before becoming confirmed figures
Other Korro Bio, Inc. 8-K Filings
Get deeper insights on Korro Bio, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.